Insights Into Hepatocellular Carcinoma (HCC)
Perspectives on drivers in treatment decisions in the management of HCC
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Southwest
More Information
- Virtual series
- Puerto Rico
More Information
- Virtual series
- Denver, St. Louis, Kansas, Oklahoma
More Information
- Virtual series
- Midwest Region
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Baltimore, Philadelphia
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of HCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
